Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
RadioTherapeutics acquisition announced Nov. 8 includes a radiofrequency ablation system for non-resectable liver lesions. Boston Scientific has distributed the system in the U.S. for radiological applications under a 1998 strategic alliance. Terms of the deal, set to close in December, were not disclosed...
You may also be interested in...
Boston Scientific Inks Smart Therapeutics Deal, Closes On Radiotherapeutics
Boston Scientific plans to combine its GDC aneurysm coils with Smart Therapeutics, Inc.'s development-phase intracranial stent system to better treat intracranial aneurysmal disease under a definitive acquisition agreement, announced Dec. 13
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.